Analyst
Wolf Research, LLC
Equibles does not estimate personal net worth.
Rudy Lee is recorded as Analyst at Wolf Research, LLC. Rudy Lee has spoken on 5 earnings calls across 5 companies, most recently for Amylyx Pharmaceuticals, Inc. on November 5, 2026. Those appearances were for Amylyx Pharmaceuticals, Inc. (AMLX), Acadia Pharmaceuticals Inc (ACAD), Denali Therapeutics Inc. (DNLI), Alkermes plc. (ALKS) and Neurocrine Biosciences Inc (NBIX). The companies whose calls Rudy Lee spoke on are classified in the Healthcare sector.
“Can you maybe provide more color on the Uncover the Mystery of PBH campaign? Were you able to locate more patients in your database, and how many healthcare professionals have signed up?”
“Just a quick follow-up for LBDP Phase II readout. Can you talk about the powering difference of this study versus the Phase II ADP trial?”
“Maybe just another quick follow-up question for the DNL 628 data in the first half. Can you determine the dosing regimen based on CSF tau data, or do you need to wait for additional biomarker imaging data to mature?”
“Just a quick follow-up question on 7290's MDD study. So, J&J showed good efficacy data in MDD for its orexin antagonist, but in patient with insomnia. Can maybe talk about the rationale for orexin agonist for MDD?”
“So for PWS, can you provide additional color on the girls' trajectory for WICAT into fourth quarter, 2027, when patient starts and discontinuation rates? Should we expect meaningful sequential growth from fourth quarter into 2027, or is it most likely into the second Thanks.”
Wolf Research, LLC
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
